Cumulative Index 1989

Volume 9

April TRANSPLANTATION IMMUNOLOGY, pages 1–233
August AIRBORNE ALLERGENS, pages 235–416
December URTICARIA AND THE EXOGENOUS DERMATOSES, pages 417–616

Note: Page numbers of issues and articles are in **boldface** type.

Acid anhydrides, as allergens, 237–239
Acrylic bone cement, 539–540
Actinomycetes-induced hypersensitivity pneumonitis, **285–306**
  bagassosis, 291
  clinical aspects, 287–290
    clinical forms of hypersensitivity pneumonitis, 288–289
    environment, 288
    historical background, 287–288
    pathology, 287
    physiology, 287
    radiology, 289
    treatment, 289–290
  diagnosis, 293–303
    immunology, 298–300
    microbiology, 293–298
    serologic methods, 300–303
  farmer's lung, 290
  immunological responses, 292–293
  mushroom worker's lung, 291
  pathogenesis, 293
  thermophilic actinomycetes as inhalant allergens, 286–287
  ventilation system pneumonitis, 291–292
Aeroallergens. See *Allergens, airborne.*
Agar gel diffusion of thermophilic actinomycetes, 300
Age, and irritant dermatitis syndrome, 439
Air pollution in California, 366–367
Airborne contact dermatitis, and sesquiterpene-lactone dermatitis, 452–454
Alcohol, and allergic dermatitis in medical personnel, 538–539
Algae of Florida, 392–393
Allergens, airborne, **235–416**
  actinomycetes-induced hypersensitivity pneumonitis, **285–306**
    clinical aspects, 287–290
    diagnosis, 293–303
    diseases caused by, 290–292
    immunologic responses, 292–293
    pathogenesis, 293
    thermophilic actinomycetes as inhalant allergens, 286–287
  animal, **357–364**
    cat, 358–359
    dog, 359–360
    guinea pig, 361
    mouse, 361
    rat, 360–361
    treatment, 361–362
  of California, **365–380**
    air pollution, 366–367
    climate, 366
    geography, 365
    grasses, 371–372
    indoor indigenous exposure, 373–379
    mold spore counts, 372–373
    pollen prevalence, 368–370
    seasonal variation, 367
    trees, 368–370
    weeds, 371
  chemical inhalants, **235–244**
    acid anhydrides, 237–239
    colophony, 240
    complex metallic salts, 239–240
    immunology, 235–237
    isocyanate hypersensitivity, 240–241
    plicatic acid, 241
  of Florida, **381–397**
    algae, 392–393

Allergens *(Continued)*
airborne, of Florida, allergy relief, 394–395
ferns, 392
fungi, 393–394
grasses, 387–390
indoor allergens, 394
trees, 381–387
weeds, 390–392
fungi, **307–319**
aerobiological determinants of exposure, 317–318
allergenic, 309–311
ecology, 316–317
nomenclature, 315–316
role of, 308–309
structure and biochemistry, 308
terminology, 307–308
immunoassays of, **269–283**
cat allergens, 277, 279
indoor allergens, 279
laboratory animals, 280–281
major allergens, 271–272
mite sensitivity, 277
sampling techniques, 273–276
in indoor air, **399–412**
allergic nonrespiratory disease, 402
allergic respiratory disease, 401–402
infectious diseases, 402–403
sick-building syndrome, epidemiology of, 403–409
industrial hygiene, 409–410
insect-derived, **321–338**
antigens as disseminated aeroallergens, 329–332
domestic or recreational, 326–329
immunochemistry, 332–333
local or indoor exposures to, 322–326
microscopy and culture, **245–268**
air sampling, designs, 263–265
equipment, 246–256
cultural analysis, 260–263
interpretation, 265
microscopic analysis, 256–260
mites, house dust, **339–356**
active uptake of water vapor, 351
characteristics of, 347
identification of, 344–347
life cycle, 343–344
and other Acari, 339–340
prevalence of, 340–343
water balance physiology and ecologic implications, 347–349, 351
allergic contact dermatitis, 580–581
poison ivy and poison oak allergic contact dermatitis, 499–501
See also *Patch test standardization.*
Allergic contact dermatitis, **579–595**
allergens, 580–581
basophils, 585
classification, 579–580
cytokines and effector cells, 582–584
down-regulation of immune response, 586–588
Langerhans cell, 581
and T-cell interaction, 581–582
mast cells, 584–585
transfer factor, 585–586
Allergic dermatoses in medical professions, **535–542**
antiseptics, 537–539
alcohol, 538–539
benzalkonium chloride, 539
chlorhexidine, 538
glutaraldehyde, 537–538
hexachlorophene, 539
povidone-iodine (Betadine), 538
contact allergens in medical specialties, 539–541
acrylic bone cement and hand dermatitis in orthopedic surgeons, 539–540
contact urticaria in animal research personnel, 540–541
formaldehyde dermatitis in renal dialysis unit personnel, 541
nitrogen mustard dermatitis in dermatologists, 540
rubber glove dermatitis, 535–537
contact urticaria, 536–537
delayed eczematous dermatitis, 535–536
Allergy relief, in Florida, 394–395
Allografts, without chimerism, 64–66
immune response to, 10
necrosis of, 11–14
rejection response mechanism, 62–63
pancreatic islet, disease recurrence, 174–175
in quadruple immunosuppressive therapy in renal transplants, 130
rejection in islet transplantation, 166–173
passenger leukocyte concept, 169–170
tissue pretreatment by organ culture, 171–172
transplantation paradox, 166–167
two signal hypothesis, 167–169
vascularized organ grafts, 170–171
See also *Cytomegalovirus infection in transplant recipients.*
Alopecia areata, **543–547**
associated disorders, 543–544
clinical syndrome, 543
immunocutaneous events, 544
immunomodulation, 545
systemic immunology, 544–545
Anaphylactic reactions to insect bites, 558
Animals, aeroallergens to, **357–364**
cat, 358–359
dog, 359–360
guinea pig, 361
mouse, 361

rat, 360–361
treatment, 361–362
allergic contact urticaria in research personnel, 540–541
skin, immediate contact reactions, 472–473
Ant bites, 560
Antibodies, in graft rejection, 13–14
and tolerance suppression, 73
Antigenicity, of grafts, 67–68
Antigens, insect, 329–332
thermophilic actinomycetes, 299–300
Antiseptics, and allergic dermatitis in medical personnel, 537–539
Aplastic anemia, bone marrow transplantation for, 196–198
Atopic dermatitis, 440
and occupational and contact allergy, 482–484, **523–534**
clinical studies, 528–530
and contact allergy, 525–527
and irritant contact dermatitis, 523–525
and sesquiterpene-lactone dermatitis, 455–456
Autologous marrow transplantation, 203–204

Baboon syndrome, 507–508
Bacteria, airborne infectious diseases, 402–403
culture of, 262–263
Bagassosis, 291
Balsam of Peru, 430
Basophils in allergic contact dermatitis, 585
Bee, wasp, and hornet bites, 560
Benzalkonium chloride, allergic dermatitis in medical personnel, 539
Binary response variables, 213–216
Black fly bites, 559
Black rubber mix, 431
Blood transfusions, and HLA matching in renal transplantation, 53–54
Bone marrow transplantation, **187–208**
basic principles, 188–196
engraftment or rejection, 189–190
graft-versus-host disease, 190–193
HLA role, 188
immunologic recovery, 194–196
infections, 193–194
pneumonia, idiopathic interstitial, 194
recipient conditioning, 188–189
for hematologic diseases, 196–205
aplastic anemia, 196–198
autologous marrow transplantation, 203–204
congenital diseases, 204–205
leukemia, acute lymphocytic, 198–199
acute nonlymphocytic, 200–201
chronic myelogenous, 201
from partially matched or unrelated donors, 201–202
lymphoma, 202–203
Botany of poison ivy and poison oak allergic contact dermatitis, 497–499
Bronchial healing, in lung transplantation, 159–160
Butterfly and moth bites, 561
p-tert-Butylphenol formaldehyde resin, 430

Caine mix, 428–429
California, aeroallergens of, **365–380**
air pollution, 366–367
climate, 366
geography, 365
grasses, 371–372
indoor indigenous exposure, 373–379
mold spore counts, 372–373
pollen prevalence, 368–371
seasonal variation, 367
weeds, 371
Carba mix, 431
Cat allergens, 358–359
immunoassays, 277, 279
CD3 and T-cell receptor complex, in graft rejection, 5
CD4 cells, in graft rejection, 9–10
Chemical inhalants, **235–244**
acid anhydrides, 237–239
colophony, 241–242
complex metallic salts, 239–240
immunology, 235–237
isocyanate hypersensitivity, 240–241
plicatic acid, 242
Children, sesquiterpene-lactone dermatitis, 451
Chimerism, 63–64
and organ allografts, 64–66
Chlorhexidine, 538
Chromium, in patch test standardization, 428
systemic contact allergy reactions, 510–511
Classification of fungi, 311–315
Climate of California, 366
Clonal deletion, and tolerance in organ transplantation, 69–70
Closed-building syndrome, 488–490
Cobalt, in patch test standardization, 430
systemic contact allergy reactions, 511
Colophony, 241–242, 429
Colormeters, 599
Congenital diseases, bone marrow transplantation in, 204–205
Contact allergy, and atopic dermatitis, 525–527
guinea pig sensitization assays, 564–566
See also *Atopic dermatitis and occupational and contact allergy.*

Corn starch surgical glove powder, 536–537
Culture of aeroallergens, 260–263
  bacteria, 262–263
  culturing ability, 260–262
  fungi, 262
  viability, 260
Cyclosporine, **79–92**
  allergic contact dermatitis, 587–588
  and cytokine gene expression, 39–40
  and lymphocyte function, 79–83
  nephrotoxicity, 88–90
  and OKT3 treatment, 100
  subcellular effects, 83–85
Cytokine release syndrome, 96–97
Cytokines, in allergic contact dermatitis, 582–584
  and lymphocyte activation, **21–43**
    mechanisms, 33–41
      cellular activation, 33–37
      gene structure and function, 37–41
    structures and functions of, 21–33
      in antigen-specific immune responses, 22–23
      clearance from circulation, 23
      cross-reactivity, 31–32
      granulocyte-macrophage colony-stimulating factor, 29
      in immune response, 32–33
      interferons, 29–30
      interleukin-1, 24–25
      interleukin-2, 25–27
      interleukin-3, 27
      interleukin-4, 27
      interleukin-5, 27–28
      interleukin-6, 28–29
      lymphocyte responses, 23
      structural features, 21–22
      synergistic functions, 32
Cytomegalovirus infection in transplant recipients, **137–151**
  and allograft dysfunction, 144–145
  clinical presentation, 140–143
  epidemiology, 138–140
  factors affecting severity, 144
  prevention of, 145–147
  treatment, 147–148
  virus characteristics, 137–138

Dermatitis, contact, patch test value, **549–554**
  formaldehyde, in renal dialysis unit personnel, 541
  hand, in orthopedic surgeons from acrylic bone cement, 539–540
  nitrogen mustard, 540
  poison ivy/oak, 497–506
  rubber glove, 535–537
  sesquiterpene-lactone. See *Sesquiterpene-lactone dermatitis.*
  See also *Allergic contact dermatitis; Irritant dermatitis syndrome.*
Dermatophagoides spp., 276–277, 339–356
Diabetes mellitus, insulin-dependent. See *Pancreatic islet transplantation in diabetes mellitus.*
Dog allergens, 359–360
Donor selection for lung transplantation, 157–158
Down-regulation, in allergic contact dermatitis, 586–588
Dust, in sesquiterpene-lactone dermatitis, 454

Ecology, fungal, 316–317
Eczemas, hypertrophic hand, occupational, 485–486
  and irritant dermatitis syndrome, 440
  rubber glove dermatitis, 535–536
Effector cells, in allergic contact dermatitis, 582–584
Environment, actinomycetes-induced hypersensitivity pneumonitis, 288
  and irritant dermatitis syndrome, 439
  and scleroderma, 486–488
Enzyme-linked immunosorbent assay (ELISA), thermophilic actinomycetes antibodies, 300–303
Epidemiology of cytomegalovirus infection in allograft recipients, 138–140
Epoxy resin, 429
Erythema, nonvisual quantification of, 597–599
Ethylenediamine, 430
Etiology of immediate contact reactions, 466–471
Euroglyphus spp., 339–356
Exposure, in irritant dermatitis syndrome, 437–438

Faenia rectivirgula, 294–295
Farmer's lung, actinomycetes-induced, 290
Ferns of Florida, 392
Flea bites, 560–561
Florida, aeroallergens of, **381–397**
  algae, 392–393
  allergy relief, 394–395
  ferns, 392
  fungi, 393–394
  grasses, 387–390
  indoor allergens, 394
  trees, 381–387
  weeds, 390–392
Follicular irritant dermatitis, 437
Formaldehyde, dermatitis in renal dialysis unit personnel, 541
  in patch test standardization, 432

Fragrance mix, 429
Free radicals, in pancreatic islet transplantation, 179–182
Fungi, airborne allergenic, **307–319**
aerobiological determinants of exposure, 317–318
allergenic, 309–311
classification, 311–315
relation to allergenicity, 314–315
ecology, 316–317
indoors, 317
outdoors, 316–317
nomenclature, 315–316
role of, 308–309
structure and biochemistry, 308
terminology, 307–308
culture of, 262
of Florida, 393–394
microscopic analysis, 258–259

Genes, cytokine, 37–41
cyclosporine effects, 39–40
expression, 39–40
mRNA instability, 40–41
regulation of expression, 39
regulatory regions, 38
structure, 37–38
Genetics of guinea pig sensitization assays, 566
Geography of California, 365
Glucocorticoids, in allergic contact dermatitis, 587
Glutaraldehyde, allergic dermatitis in medical personnel, 537–538
Graft rejection, molecular immunology of, **1–19**
clinical varieties, 14–16
hyperacute, 14
process and mechanisms of, 9–14
allograft necrosis, 11–14
CD4 T-cell triggering by antigen-presenting cells, 9–10
immune response to allograft, 10
inflammatory infiltrate, 10–11
major histocompatibility complex, 11
significance of, 16
T-cell system, 5–9
antigen recognition, 5
lymphocyte functions, 8–9
targets of rejection, 2–4
major histocompatibility complex, 2
regulation of expression, 3–4
structure of genes and products, 2–3
Graft-versus-host disease, bone marrow transplantation, 190–193
bone marrow treatment, 191–192
clinical presentation, 190–191
patient problems, 192–193
prevention of, 191
Granulocyte-macrophage colony-stimulating factor, 29
Grasses, of California, 371–372
of Florida, 387–390
Growth factors, and cytokine activation, 33–34
Guinea pig, allergens, 361
sensitization data in office practice, **563–577**
contact allergy factors, 564–566
dosage and concentration, 565–566
genetics, 566
mode and route of exposure, 566
physico-chemical properties, 564
vehicle, 566
sensitization assays, 563–564, 567–574
epicutaneous methods, 568–570
intradermal methods, 567–568

Hexachlorophene, allergic dermatitis in medical personnel, 539
HLA matching, in bone marrow transplantation, 188, 196–198
in quadruple immunosuppressive therapy in renal transplants, 124
in renal transplantation, **45–60**
matching versus mismatching, 51–52
short-term versus long-term effects, 52–53
House dust mites. See *Mites, house dust.*

Immediate contact reactions, **463–478**
in animal skin, 472–473
diagnostic tests, 471–472
for immunologic reactions, 471–472
and nonimmunologic reactions, 471
etiology, 466–471
irritant contact dermatitis, 436–437
symptoms, 463–466
immunologic, 464–465
nonimmunologic, 465–466
protein contact, 465
Immune response, cytokine function, 22–23, 32–33
Immunoassays of airborne allergens, **269–283**
major allergens, 271–272
mite sensitivity, 276–277
sampling techniques, 273–276
cascade impactors and impingers, 274–275
cat allergens, 277, 279
falling studies, 275–276
indoor allergens, 279
laboratory animal allergens, 280–281
particle sizing, 274, 276
sieves, 274
volumetric samplers, 273–274

Immunogenicity of OKT3, 97–98
Immunologic immediate contact reactions, 464–465
  diagnostic tests, 471
Immunology, of actinomycetes-induced hypersensitivity pneumonitis, 292–293, 298–300
  of chemical inhalants, 235–237
  insect allergens, 332–333, 555–558
Immunomodulation, in alopecia areata, 545
Immunosuppression, in lung transplantation, 158
  quadruple therapy in renal transplants, **109–135**
    allograft function, 130
    antilymphocyte therapy, 112
    early graft function, 119–123
    HLA matching, 124
    infections, 126–128
    limitations of current regimens, 131–132
    morbidity, 129
    OKT3 effects, 123–124, 132
    organ procurement and preservation, 115
    patient and graft survival, 118–119
    protocol, 115–116
    recipient selection criteria, 113–114
    rejection, 117, 125–126
    results and expectations, 130–131
    sensitization, 124–125
    statistical analysis, 117–118
    strategies of methods, 111–112
    study population, 112–113
    study variables, 117
  See also *Cyclosporine*.
Impactors, cascade, 274–275
  centrifugal, 254
  rotating-arm, 248–250
  suction, 250
Impingers, cascade, 274–275
  liquid, 255
Indoor air, allergic and infectious agents, **399–412**
  allergic nonrespiratory disease, 402
  allergic respiratory disease, 401–402
  in California, 373–379
  Florida allergens, 394
  fungal ecology, 317
  immunossays, 279
  infectious diseases (bacterial), 402–403
  insect-derived allergens, 322–326
  sick-building syndrome, epidemiology of, 403–409
    cross-sectional studies, 403–404
    microenvironment, 405–407
    panel studies, 404–405
    psychosocial factors, 408–409
    volatile organic compounds, 407–408
  industrial hygiene, 409–410
Industrial hygiene, sick-building syndrome, 409–410
Infections, in bone marrow transplantation, 193–194
  and OKT3 treatment, 102
  in quadruple immunosuppressive therapy in renal transplants, 126–128
  See also *Cytomegalovirus infection in transplant recipients*.
Inflammation, in graft rejection, 12–13
Inflammatory infiltrate, 10–11
Insect bite reactions, **555–562**
  immune system, 555–558
    anaphylactic reactions, 558
    nodular reactions, 557–558
    papular reactions, 556–557
    vasculitic reactions, 557
    wheal reactions, 556
  nonimmunologic reactions, 559
  specific reactions, 559–561
    ants, 560
    bees, wasps, and hornets, 560
    black flies, 559
    butterflies and moths, 561
    fleas, 560–561
    midges, 559
    mosquitoes, 559
    sand flies, 559
  treatment, 561–562
Insect-derived allergens, **321–338**
  antigens as disseminated aeroallergens, 329–332
  domestic or recreational inhalant insect allergy, 326–329
  immunochemistry, 332–333
  local or indoor exposures to, 322–326
    occupational morbidity, 322–326
Interferons, 29–30
Interleukin-1, 24–25
Interleukin-2, 25–27
  high-affinity receptor, 30–31
Interleukin-3, 27
Interleukin-4, 27
Interleukin-5, 27–28
Interleukin-6, 28–29
Irritant dermatitis syndrome, **435–445**
  and atopic dermatitis, 523–525
  clinical irritant contact dermatitis, 435–437
    acute irritant dermatitis, 436
    acute irritant reaction, 436
    follicular irritant dermatitis, 437
    immediate contact irritation (contact urticaria), 436–437
    importance of, 435
    irritation from repeated exposure, 437
    occurrence of, 436
  endogenous factors, 439–441
    age, 439
    race, 440

sex, 439–440
systemic skin disease, 440–441
environmental role, 439
exposure, 437–438
airborne, 438
open and occluded, 437–438
repeated, 438
simultaneous, 438
irritants, 437
spatial variation, 438–439
studies, clinical, 441
experimental, 441–442
Isocyanate hypersensitivity, 240–241

Kathon CG, 431

Laboratory animal allergens, 280–281
Langerhans cell, in allergic contact dermatitis, 581–582
Laser Doppler velocimetry, 597–598
Latex rubber glove urticaria, 536
Leukemia, bone marrow transplantation for, 198–202
acute lymphocytic, 198–199
acute nonlymphocytic, 200–201
chronic myelogenous, 201
in partially matched or unrelated donors, 201–202
Liquid impingers, 255
Lung transplantation, **153–163**
double, 160–162
functional outcome, 161–162
patient selection, 160–161
in humans, 154–155
single, 155–160
bronchial healing, 159–160
donor selection, 157–158
functional outcome, 159
immunosuppression, 158
recipient selection, 155–157
rejection, 158–159
Lymphocytes, and cyclosporine immunosuppression, 79–83
in graft rejection, 8–9
See also *Cytokines, and lymphocyte activation.*
Lymphoma, bone marrow transplantation for, 202–203

Major histocompatibility complex (MHC), and graft rejection, 2–4, 11
in pancreatic islet transplantation, 175–177
and tolerance in organ transplantation, 68–69
Males, sesquiterpene-lactone dermatitis, 451
Mast cells in allergic contact dermatitis, 584–585
Medical personnel. See *Allergic dermatoses in medical professions.*
Mercapto mix, 432
Mercaptobenzothiazole, 431–432
Metal, implanted prostheses, systemic contact allergy reactions, 512–514
Metallic salts, as allergens, 239–240
Microbiology of thermophilic actinomycetes, 293–303
Faenia rectivirgula, 294–295
Saccharomonospora viridisi, 295
Thermoactinomyces, 295–298
Microscopy and culture of aeroallergens, **245–268**
air sampling design, 263–265
air sampling equipment, 246–256
filtration samplers, 254–255
inertial samplers, 246–254
centrifugal impactors, 254
rotating-arm impactors, 248–250
sieve-type viable samplers, 252–253
slit-type particulate suction sampler, 250–252
slit-type viable suction sampler, 252
suction impacters, 250
liquid impingers, 255
sampler calibration, 256
settle or "fall-out" samplers, 246
swab and source samples, 256
cultural analysis, 260–263
bacteria, 262–263
culturing ability, 260–262
fungi, 262
reporting, 263
viability, 260
interpretation, 265
microscopic analysis, 256–260
fungi, 258–259
other particulates, 259
pollen, 257–258
reporting, 259–260
Midge bites, 559
Mites, in house dust, **339–356**
active uptake of water vapor, 351
characteristics, 347
identification of, 344–347
immunoassays, 277
life cycle, 343–344
and other Acari, 339–340
prevalence of, 340–343
water balance physiology and ecologic implications, 347–349, 351
Mold spores, in California, 372–373
Molecular immunology of transplantation, **1–19**
graft rejection, 9–14
allograft necrosis, 11–14

Molecular immunology of transplantation *(Continued)*
graft rejection, CD4 T-cell triggering by antigen-presenting cells, 9–10
clinical varieties, 14–16
immune response to allograft, 10
inflammatory infiltrate, 10–11
major histocompatibility complex, 11
significance of, 16
T-cell system, 5–9
antigen recognition, 5
lymphocyte functions, 8–9
targets of rejection, 2–4
major histocompatibility complex, 2
regulation of expression, 3–4
structure of genes and products, 2–3
Morbidity, in quadruple immunosuppressive therapy in renal transplants, 129
Mosquito bites, 559
Mouse allergens, 361
Mushroom worker's lung, 291
Mycosis fungoides, 490–492

Neomycin, in patch test standardization, 428
Nephrotoxicity, cyclosporine-induced, 88–90
Nickel, in patch test standardization, 428
systemic contact allergy reactions, 508–510
Nitrogen mustard dermatitis, 540
Nomenclature of fungi, 315–316
Nonimmunologic immediate contract reactions, 465–466
diagnostic tests, 471
to insect bites, 559

Occupational dermatology, **479–496**
atopy role, 482–484
"closed-building syndrome," 488–490
environmental causes for scleroderma, 486–488
hypertrophic hand eczema, 485–486
insect-derived allergens, 322–326
mycosis fungoides, 490–492
patch tests, 479–482
ultraviolet light and skin cancer, 484–485
video display terminal screens, 492–493
OKT3, **95–107**
properties of, 95–98
clearance/disappearance of, 96
cytokine release syndrome, 96–97
immunogenicity, 97–98
mechanisms of action, 95–96
T-cell clearance/modulation, 96
in quadruple immunosuppressive therapy in renal transplants, 123–124, 132
safety, 102
infections, 102
therapeutic uses of, 98–102
and cyclosporine, 100
primary treatment of rejection, 98–99
prophylaxis, 100–101
re-rejection, 99
resistant rejection, 99–100
second re-treatment course, 101–102
Organ culture, tissue pretreatment, in pancreatic islet transplantation, 171–172
Organ procurement and preservation, in quadruple immunosuppressive therapy in renal transplants, 115
Organ transplantation. See *Tolerance and unresponsiveness in organ transplantation.*
Organic compounds, volatile, in sick-building syndrome, 407–408
Orthopedic surgeons, hand dermatitis from acrylic bone cement, 539–540
Outdoor environment, fungal ecology, 316–317

Packing material, in patch tests, 424
Pancreatic islet transplantation in diabetes mellitus, **165–186**
allograft rejection, 166–173
pancreatic islet transplantation, 172–173
passenger leukocyte concept, 169–170
tissue pretreatment by organ culture, 171–172
transplantation paradox, 166–167
two signal hypothesis, 167–169
vascularized organ grafts, 170–171
disease recurrence, 173–182
in cultured islet allografts, 174–175
free radical involvement, 179–182
MHC restriction of, 175–177
T-cell subsets, 177–179
Parabens, in patch test standardization, 430–431
Paraphenylenediamine, in patch test standardization, 428
Particle sizing, 273–274, 276
Passenger leukocyte concept, 169–170
Patch tests, in contact dermatitis, **549–554**
for immediate contact reactions, 471
in occupational dermatology, 479–482
for sesquiterpene-lactone dermatitis, 456–457
standardization, **417–434**
allergens, 421–433
clinical standardization, dose response studies, 419, 424–425
irritant reactions and accuracy, 425–427
clinical verification, 427
packing of test material, 424
pharmaceutical preparations, 422–423

preformulation, 422
sensitization risk, 427
stability and quality control, 423
tape, 424
vehicle, 423–424
in vitro standardization of dose, 423
allergic and irritant reactions, 418–419
reasons for, 417–418
standard allergens and allergen mixes, 428–433
balsam of Peru, 430
black rubber mix, 431
p-tert-butylphenol formaldehyde resin, 430
caine mix, 428–429
carba mix, 431
chromium salts, 428
cobalt, 430
colophony, 429
epoxy resin, 429
ethylenediamine, 430
formaldehyde, 432
fragrance mix, 429
Kathon CG, 431
Mercapto mix, 432
mercaptobenzothiazole, 431–432
neomycin, 428
nickel, 428
parabens, 430–431
paraphenylenediamine, 428
Quaternium-15, 431
Quinoline mix, 432–433
thiomersal, 432
thiuram mix, 429–430
wool alcohols, 432
systemic contact allergy reactions, 507
systems, 419–421
application method, 419–421
TRUE test, 420–421
present standardization, 421
technique, 418
Photosensitivity, and sesquiterpene-lactone dermatitis, 455
Plants, sesquiterpene-lactone dermatitis, 452
Plicatic acid, 242
Pneumonia, idiopathic interstitial, in bone marrow transplantation, 194
Pneumonitis, hypersensitivity. See *Actinomycetes-induced hypersensitivity pneumonitis.*
Poison ivy/oak allergic contact dermatitis, **497–506**
allergens, 499–501
botany, 497–499
poison ivy/oak dermatitis, 501–503
prevention, 503–504
treatment, 504–505
Pollen, in California, 368–370
microscopic analysis, 257–258
Pompholyx, 507
Povidone-iodine (Betadine), allergic dermatitis, 538
Prick testing, 471
Prostheses, implanted metal, systemic contact allergy reactions, 512–514
Protein contact dermatitis, 465
Psoriasis, and irritant dermatitis syndrome, 440–441
Psychosocial factors, in sick-building syndrome, 408–409

Quality control, in patch test standardization, 423
Quaternium-15, 431
Quinoline mix, 432–433

Race, and irritant dermatitis syndrome, 440
RAST test, 472
Rat allergens, 360–361
Receptors, for cytokine, 30–31
Recipient selection criteria, in lung transplantation, 155–157, 160–161
quadruple immunosuppressive therapy in renal transplants, 113–114
Regression models, 212–213
relative risk, 219–220
Rejection, in bone marrow transplantation, 189–190
in lung transplantation, 158–159
OKT3 treatment, 98–100
in quadruple immunosuppressive therapy in renal transplants, 117, 125–126
Renal dialysis, and formaldehyde dermatitis, 541
Renal transplantation. See *HLA matching in renal transplantation; Immunosuppression, quadruple therapy in renal transplants.*
Respiratory disease, allergic, in indoor air, 401–402
RNA, messenger-, cytokine, 40–41
Rotating-arm impactors, 248–250
Rub test, 471
Rubber glove dermatitis, 535–537
contact urticaria, 536–537
delayed eczematous, 535–536

Saccharomonospora viridis, 295
Samplers, for aeroallergens, 246–256
calibration of, 256
design of, 263–265
filtration, 254–255
inertial, 246–254
centrifugal impactors, 254

Samplers *(Continued)*
inertial, rotating-arm impactors, 248–250
sieve-type viable, 252–253
slit-type particulate suction, 250–252
slit-type viable suction, 252
suction impactors, 250
liquid impingers, 255
settle or "fall-out," 246
swab and source samples, 256
volumetric, 273–274
Sand fly bites, 559
Scleroderma, environmental causes, 486–488
Scratch tests, 471–472
Scratch-chamber test, 472
Sensitization assays, guinea pig, 563–564
Sesquiterpene-lactone dermatitis, **447–461**
clinical picture, 450–456
airborne contact dermatitis, 452–454
atopy role, 455–456
causes of, 451–452
in children, 451
dust factor, 454
in males, 451
occurrence, 450–451
photosensitivity, 455
and plants, 452
species involvement, 456
patch testing, 456–457
Sex, and irritant dermatitis syndrome, 439–440
Sick-building syndrome, epidemiology of, 403–409
cross-sectional studies, 403–404
microenvironment, 405–407
panel studies, 404–405
psychosocial factors, 408–409
volatile organic compounds, 407–408
industrial hygiene, 409–410
Sieves, 274
viable samplers, 252–253
Skin cancer, in occupational dermatology, 484–485
Skin disease, and irritant dermatitis syndrome, 440–441
See also *Alopecia areata*.
Skin tests, nonvisual quantification, **597–603**
erythema, 597–599
colormeters, 599
laser Doppler velocimetry, 597–598
remittance spectroscopy, 598–599
skin thickness, 599–600
transepidermal water loss, 600–601
Spectroscopy, remittance, 598–599
Statistical analysis, in quadruple immunosuppressive therapy in renal transplants, 117–118
of transplantation data, **209–227**
binary response variables, 213–216
extensions for more than two outcome categories, 217–218
matched studies, 216–217
regression models, 212–213
sources of data, 210–211
survival curves and two-group comparisons, 211–212
time-to-event data, 218–226
cause-specific failure rates, 224–226
relative risk regression models, 219–220
stratification, 220–222
time-dependent covariates, 222–224
Suppressor mechanisms, and tolerance in organ transplantation, 70–73
Survival curves, 211–212
Swab samples, 256
Systemic contact allergy reactions, **507–522**
chromium, 510–511
clinical picture, 507–508
baboon syndrome, 507–508
flare-ups of patch test and contact dermatitis reactions, 507
pompholyx, 507
systemic symptoms, 508
vasculitis, 508
cobalt, 511
diagnosis, 517–518
implanted metal prostheses, 512–514
mechanism, 517
medications, 514–516
nickel, 508–510
toxicologic assays, 518

T cells, and graft rejection, 5–9
antigen recognition, 5
lymphocyte functions, 8–9
OKT3 effect on clearance/modulation, 96
subsets, in pancreatic islet transplantation, 177–179
Tape, in patch test standardization, 424
Terminology of fungi, 307–308
Thermoactinomyces, 295–298
Thiomersal, 432
Thiuram mix, 429–430
Time-to-event data, 218–226
cause-specific failure rates, 224–226
relative risk regression models, 219–220
stratification, 220–222
time-dependent covariates, 222–224
Tolerance and unresponsiveness in organ transplantation, **61–77**
allograft rejection response, 62–63
antibody mediation, 73
clonal deletion, 69–70
graft antigenicity, 67–68
models of, chimerism, 63–64
allograft without chimerism, 64–66
soluble MHC molecules, 68–69
suppressor mechanisms, 70–73

Toxicology, systemic contact allergy reactions, 518
Transfer factor, in allergic contact dermatitis, 585–586
Transplantation immunology, **1–233**
bone marrow transplantation, **187–208**
basic principles, 188–196
for hematologic diseases, 196–205
cyclosporine, **79–92**
and lymphocyte function, 79–83
nephrotoxicity, 88–90
at subcellular level, 83–85
cytokines, and lymphocyte activation, **21–43**
mechanisms, 33–41
structure and function, 21–33
cytomegalovirus infections, **137–151**
and allograft dysfunction, 144–145
clinical presentation, 130–143
epidemiology, 138–140
factors affecting severity, 144
prevention of, 145–147
treatment, 147–148
virus characteristics, 137–138
HLA matching in renal transplantation, **45–60**
matching versus mismatching, 51–52
short-term versus long-term effects, 52–53
islet transplantation in diabetes mellitus, **165–186**
allograft rejection, 166–173
disease recurrence, 173–182
lung transplantation, **153–163**
double lung, 160–162
in humans, 154–155
single lung, 155–160
molecular immunology of, **1–19**
clinical varieties of rejection, 14–16
graft rejection, 9–14
significance of graft rejection, 16
T-cell system, 5–9
targets of rejection, 2–4
OKT3, **95–107**
properties of, 95–98
safety of, 102
therapeutic uses of, 98–102
quadruple immunosuppressive therapy in renal transplants, **109–135**
allograft function, 130
early graft function, 119–123
HLA matching, 124
infection, 126–128
limitations, 131–132
materials and methods, 112–117
morbidity, 129
OKT3 effects, 123–124, 132
overview of methods, 111–112
patient and graft survival, 118–119
rejection, 125–126
results and expectations, 130–131
sensitization, 124–125
statistical analysis, 177–188, **209–227**
classification outcomes, 213–218
regression models, 212–213
sources of data, 210–211
survival curves and two-group comparisons, 211–212
time-to-event data, 218–226
tolerance and unresponsiveness in organ transplantation, **61–77**
allograft rejection response, 62–63
antibody mediation, 73
clonal deletion, 69–70
maintenance of, 67–68
models of transplantation tolerance, 63–66
soluble major histocompatibility complex molecules, 68–69
suppressor mechanisms, 70–73
Trees, in California, 368–370
of Florida, 381–387
Trimellitic anhydride, 237
TRUE test, 420–421
Two-group comparisons, 211–212

Ultraviolet radiation, in allergic contact dermatitis, 586–587
in occupational dermatology, 484–485
Unresponsiveness. See *Tolerance and unresponsiveness in organ transplantation.*
Urticaria and exogenous dermatoses, **417–616**
allergic contact dermatitis, mechanisms of, **579–595**
allergens, 580–581
basophils, 585
classification, 579–580
cytokines and effector cells, 582–584
down-regulation of immune response, 586–588
Langerhans cell and T-cell interaction, 581–582
Langerhans cell, 581
mast cells, 584–585
transfer factor, 585–586
allergic dermatoses in medical professions, **535–542**
from antiseptics, 537–539
rubber glove dermatitis, 535–537
specialized contact allergens, 539–541
alopecia areata, **543–547**
associated disorders, 543–544
clinical syndrome, 543
immunocutaneous events, 544
immunomodulation, 545
systemic immunology, 544–545

Urticaria and exogenous dermatoses *(Continued)*
atopic dermatitis and occupational and contact allergy, **523–534**
atopic dermatitis, and contact allergy, 525–527
and irritant contact dermatitis, 523–525
clinical studies, 528–530
contact allergies, 564–566
guinea pig sensitization data in office practice, **563–577**
guinea pig sensitization assays, 567–574
sensitization assays, 563–564
immediate contact reactions, **463–478**
in animal skin, 472–473
diagnostic tests, 471–472
etiology, 466–471
symptoms, 463–466
insect bites, **555–562**
anaphylactic reactions, 558
immune system, 555–558
nonimmunologic reactions, 559
specific reactions, 559–561
treatment, 561–562
irritant dermatitis syndrome, **435–445**
clinical irritant contact dermatitis, 435–437
endogenous factors, 439–441
environmental role, 439
experimental studies, 441–442
exposure, 437–438
irritants, 437
spatial variation, 438–439
nonvisual quantification of skin tests, **597–603**
erythema, 597–599
skin thickness, 599–600
transepidermal water loss, 600–601
occupational dermatology, **479–496**
atopy role, 482–484
"closed-building syndrome," 488–490
environmental causes for scleroderma, 486–488
hypertrophic hand eczema, 485–486
mycosis fungoides, 490–492
patch testing, 479–482
ultraviolet light and skin cancer, 484–485
video display terminal screens, 492–493
patch tests, value in contact dermatitis, **549–554**
standardization, **417–434**
allergen characterization, 421–433
allergen dose, 419
allergic and irritant reactions, 418–419
patch test systems, 419–421
reasons for, 417–418
technique, 418
poison ivy and poison oak allergic contact dermatitis, **497–506**
allergen, 499–501
botany, 497–499
poison ivy/oak dermatitis, 501–503
prevention, 503–504
treatment, 504–505
sesquiterpene-lactone dermatitis, **447–461**
clinical picture, 450–456
patch testing, 456–457
systemic contact allergy reactions, **507–522**
chromium, 510–511
clinical picture, 507–508
cobalt, 511
diagnosis, 517–518
implanted metal prostheses, 512–514
mechanism, 517
medicaments, 514–516
nickel, 508–510
toxicologic assays, 518

Vasculitis, in systemic contact allergy reactions, 508
Vehicle, in guinea pig sensitization assays, 566
in patch test standardization, 423–424
Ventilation system pneumonitis, actinomycetes-induced, 291–292
Video display terminal screens, and rosacea, 492–493

Water, physiology of, and house dust mites, 347–349
uptake of vapor, 350–351
transepidermal loss, 600–601
Weed dermatitis. See *Sesquiterpene-lactone dermatitis.*
Weeds, of California, 371
of Florida, 390–392
Wool alcohols, in patch test standardization, 432